Inovio Pharmaceuticals

Roche, Inovio Pharmaceuticals partner

Wednesday, September 11, 2013 01:35 PM

Roche and Inovio Pharmaceuticals have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development.

More... »

Inovio, U.S. Army receive $3.5M biodefense grant for mass vaccination device

Friday, April 12, 2013 11:22 AM

Inovio Pharmaceuticals has been selected to receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.

More... »

PATH Malaria Vaccine Initiative and Inovio to accelerate development of malaria vaccines

Monday, January 7, 2013 12:22 PM

The PATH Malaria Vaccine Initiative (MVI), a global program established by international nonprofit organization PATH, and Inovio Pharmaceuticals, a vaccine developer, have agreed to a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

More... »

Inovio's chairman elected fellow by AAAS

Wednesday, March 14, 2012 09:16 AM

Inovio Pharmaceuticals’ advisory board chairman David B. Weiner, PhD, has been elected a fellow in the nonprofit American Association for the Advancement of Science (AAAS).

More... »

Inovio vaccine shows long-term durability

Wednesday, July 20, 2011 11:04 AM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, has reported long-term durability of T cell immune responses of up to over two years (at the latest time measured) in seven of eight evaluated patients following a fourth vaccination of VGX-3100, its investigational SynConR DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

More... »

Inovio releases phase I flu vaccine results

Friday, July 15, 2011 10:27 AM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, announced that significant T cell and antibody responses were generated in its phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

More... »

Inovio reports positive responses from cervical dysplasia vaccine

Monday, May 9, 2011 12:48 PM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV).

More... »

Inovio Pharmaceuticals initiates phase II trial of DNA vaccine

Thursday, March 17, 2011 12:43 PM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, said its partner ChronTech Pharma  (formerly Tripep ), has initiated a phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus (HCV), delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.

More... »